tetano
Editor, Senior Moderator
Virus Res
. 2024 May 19:199402.
doi: 10.1016/j.virusres.2024.199402. Online ahead of print. Preparation and Characterization of Mouse-Derived Monoclonal Antibodies Against the Hemagglutinin of the H1N1 Influenza Virus
Xiantian Lin[SUP] 1 [/SUP], Fan Yang[SUP] 2 [/SUP], Sijing Yan[SUP] 1 [/SUP], Han Wu[SUP] 1 [/SUP], Ping Wang[SUP] 1 [/SUP], Yuxi Zhao[SUP] 1 [/SUP], Danrong Shi[SUP] 1 [/SUP], Hangping Yao[SUP] 1 [/SUP], Haibo Wu[SUP] 1 [/SUP], Lanjuan Li[SUP] 3 [/SUP]
Affiliations
H1N1 influenza virus is a significant global public health concern. Monoclonal antibodies (mAbs) targeting specific viral proteins such as hemagglutinin (HA) have become an important therapeutic strategy, offering highly specific targeting to block viral transmission and infection. This study focused on the development of mAbs targeting HA of the A/Victoria/2570/2019 (H1N1pdm09, VIC-19) strain by utilizing hybridoma technology to produce two mAbs with high binding capacity. Notably, mAb 2B2 has demonstrated a strong affinity for HA proteins in recent H1N1 influenza vaccine strains. In vitro assessments showed that both mAbs exhibited broad-spectrum hemagglutination inhibition and potent neutralizing effects against various vaccine strains of H1N1pdm09 viruses. 2B2 was also effective in animal models, offering both preventive and therapeutic protection against infections caused by recent H1N1 strains, highlighting its potential for clinical application. By individually co-cultivating each of the aforementioned mAbs with the virus in chicken embryos, four amino acid substitution sites in HA (H138Q, G140R, A141E/V, and D187E) were identified in escape mutants, three in the antigenic site Ca2, and one in Sb. The identification of such mutations is pivotal, as it compels further investigation into how these alterations could undermine the binding efficacy and neutralization capacity of antibodies, thereby impacting the design and optimization of mAb therapies and influenza vaccines. This research highlights the necessity for continuous exploration into the dynamic interaction between viral evolution and antibody response, which is vital for the formulation of robust therapeutic and preventive strategies against influenza.
Keywords: Escape mutant; Hemagglutinin; Influenza; Monoclonal antibody; Neutralization.
. 2024 May 19:199402.
doi: 10.1016/j.virusres.2024.199402. Online ahead of print. Preparation and Characterization of Mouse-Derived Monoclonal Antibodies Against the Hemagglutinin of the H1N1 Influenza Virus
Xiantian Lin[SUP] 1 [/SUP], Fan Yang[SUP] 2 [/SUP], Sijing Yan[SUP] 1 [/SUP], Han Wu[SUP] 1 [/SUP], Ping Wang[SUP] 1 [/SUP], Yuxi Zhao[SUP] 1 [/SUP], Danrong Shi[SUP] 1 [/SUP], Hangping Yao[SUP] 1 [/SUP], Haibo Wu[SUP] 1 [/SUP], Lanjuan Li[SUP] 3 [/SUP]
Affiliations
- PMID: 38772446
- DOI: 10.1016/j.virusres.2024.199402
H1N1 influenza virus is a significant global public health concern. Monoclonal antibodies (mAbs) targeting specific viral proteins such as hemagglutinin (HA) have become an important therapeutic strategy, offering highly specific targeting to block viral transmission and infection. This study focused on the development of mAbs targeting HA of the A/Victoria/2570/2019 (H1N1pdm09, VIC-19) strain by utilizing hybridoma technology to produce two mAbs with high binding capacity. Notably, mAb 2B2 has demonstrated a strong affinity for HA proteins in recent H1N1 influenza vaccine strains. In vitro assessments showed that both mAbs exhibited broad-spectrum hemagglutination inhibition and potent neutralizing effects against various vaccine strains of H1N1pdm09 viruses. 2B2 was also effective in animal models, offering both preventive and therapeutic protection against infections caused by recent H1N1 strains, highlighting its potential for clinical application. By individually co-cultivating each of the aforementioned mAbs with the virus in chicken embryos, four amino acid substitution sites in HA (H138Q, G140R, A141E/V, and D187E) were identified in escape mutants, three in the antigenic site Ca2, and one in Sb. The identification of such mutations is pivotal, as it compels further investigation into how these alterations could undermine the binding efficacy and neutralization capacity of antibodies, thereby impacting the design and optimization of mAb therapies and influenza vaccines. This research highlights the necessity for continuous exploration into the dynamic interaction between viral evolution and antibody response, which is vital for the formulation of robust therapeutic and preventive strategies against influenza.
Keywords: Escape mutant; Hemagglutinin; Influenza; Monoclonal antibody; Neutralization.